Gyrus Pharmaceuticals Private Limited
About Gyrus Pharmaceuticals Private Limited
Data last updated:
Gyrus Pharmaceuticals Private Limited is a private limited company based in Amritsar, Punjab, India. It operates in the chemical distribution and retail segment of the chemicals and materials sector. It was incorporated on 09 March 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U74999PB2017PTC046223. Its GSTIN is 09AAGCG7372Q1ZQ (Uttar Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Manjit Singh Sandhu and Manoj Kumar Singh.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Gali Gyan Singh Wali H.No – 123 Vpo – Jallupur Khaira Baba Bakala Sahib, Amritsar, Punjab, India – 143001.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.85 Lakh, a growth of 21% compared to the previous year. For the same year it recorded a net loss of ₹3.57 Lakh (net margin -61%) and EBITDA of -₹3.41 Lakh (EBITDA margin -58.2%). Revenue has grown at a compounded annual rate (CAGR) of 32% over three years and 16% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Gyrus Pharmaceuticals Private Limited's registered office is in Amritsar, Punjab. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressGali Gyan Singh Wali H.No – 123 Vpo – Jallupur Khaira Baba Bakala Sahib, Amritsar, Punjab, India – 143001
- IndustryChemicals and Materials, Chemical Distribution & Retail
To see the full contact details of Gyrus Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Gyrus Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Gyrus Pharmaceuticals Private Limited, buy the company report.
Financials of Gyrus Pharmaceuticals Private Limited
FY 2024 filings availableGyrus Pharmaceuticals Private Limited reported revenue of ₹5.85 Lakh (up 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 16% over five years, including 21% growth in the latest year. EBITDA rose 22% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹3.41 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹3.57 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -58.2% | ||||
| Net Profit Margin | -61% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Gyrus Pharmaceuticals Private Limited, buy the company report.
Board of directors of Gyrus Pharmaceuticals Private Limited
Gyrus Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manjit Singh Sandhu | Director | 09 Mar 2017 | 9 Years 8 Months | Current |
| Manoj Kumar Singh Also directs: Amfibre Solutions Private Limited | Director | 09 Mar 2017 | 9 Years 8 Months | Current |
Peer comparison
Gyrus Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Chemicals industry (Chemical Retail and Distribution, Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Parikh Synergies Private Limited | ₹5.87 Lakh (FY 2024) | -89.0% | Chennai, Tamil Nadu, India | |||
| Gyrus Pharmaceuticals Private Limitedthis company | ₹5.85 Lakh (FY 2025) | -₹3.57 Lakh | -61% | 21.0% | Amritsar, Punjab, India | |
| Maclaren Pharmaceuticals Private Limited | ₹5.84 Lakh (FY 2022) | -16.0% | Bareilly, Uttar Pradesh, India | |||
| Shree Radhey Krishna Perfumery Works Private Limited | ₹5.84 Lakh (FY 2024) | 30.0% | Indore, Madhya Pradesh, India | |||
| Avatis Pharmaceuticals (OPC) Private Limited | ₹5.83 Lakh (FY 2025) | 43.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Gyrus Pharmaceuticals Private Limited, buy the company report.
Auditor
Gyrus Pharmaceuticals Private Limited is audited by AMIT DIWAN & CO for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AMIT DIWAN & CO | FY 2021 | 028824N |
Shareholding
The shareholding of Gyrus Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2021, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2020 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Gyrus Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Gyrus Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Gyrus Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Gyrus Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAGCG7372Q1ZQ | Uttar Pradesh | Active | 14 Dec 2019 |
To see the full GST registrations and return filing status of Gyrus Pharmaceuticals Private Limited, buy the company report.
Recent activity
Gyrus Pharmaceuticals Private Limited has 3 board changes on record since 2017: 2 appointments and 1 cessation. The latest: Jai Krishna Pandey ceased to be Director on 20 Sep 2021.
Frequently asked questions
Gyrus Pharmaceuticals is an active private limited company based in Amritsar, Punjab, India. The company works in chemical distribution and retail, within the chemicals and materials industry. It was incorporated on 09 March 2017 (9+ years old) and is registered under CIN U74999PB2017PTC046223.
Gyrus Pharmaceuticals has 2 current directors:
- Manjit Singh Sandhu - Director
- Manoj Kumar Singh - Director
The latest financial statements of Gyrus Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Gyrus Pharmaceuticals is 09AAGCG7372Q1ZQ, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Gyrus Pharmaceuticals is U74999PB2017PTC046223. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Gyrus Pharmaceuticals was incorporated on 09 March 2017, making it 9+ years old. It is registered with the Registrar of Companies, Chandigarh.
The peers of Gyrus Pharmaceuticals by revenue are Parikh Synergies Private Limited, Maclaren Pharmaceuticals Private Limited, Shree Radhey Krishna Perfumery Works Private Limited, Avatis Pharmaceuticals (OPC) Private Limited, all in the Chemicals industry (Chemical Retail and Distribution, Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).
Jai Krishna Pandey ceased to be Director on 20 Sep 2021. Manjit Singh Sandhu was appointed as Director on 09 Mar 2017. Manoj Kumar Singh was appointed as Director on 09 Mar 2017.
The registered office of Gyrus Pharmaceuticals is at Gali Gyan Singh Wali H.No – 123 Vpo – Jallupur Khaira Baba Bakala Sahib, Amritsar, Punjab, India – 143001.
Gyrus Pharmaceuticals operates in the chemicals and materials industry, in the chemical distribution and retail segment.
The compliance status of Gyrus Pharmaceuticals is compliant as of 09 July 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
